The Lead Episode 105: A Discussion of Acute Safety and Effectiveness of a Novel Balloon-Based PFA Catheter in Paroxysmal and Persistent AF: Acute Results of the Volt-AF IDE Trial (Live at HRS 2025)-The Lead Episode 105 (video)

Video Transcription

Video Summary

At the Heart Rhythm Sessions in San Diego, the VOLT-AF-IDE trial results were unveiled, showing promising advancements in catheter technology for atrial fibrillation (AF) treatment. The trial evaluated Abbott's new balloon-inflatable pulse field ablation (PFA) catheter, specifically designed for pulmonary vein isolation (PVI). Conducted across 38 sites with 392 patients, the study showcased a 98.2% effectiveness in paroxysmal AF and 99.4% in persistent AF, with a safety event rate of 1.9%. Despite minor safety concerns, such as cardiac tamponade and stroke, the findings align with existing PFA trials, ensuring the technology's competitive standing in the field. The discussion explored the potential for non-invasive application, emphasizing safety and specificity to enhance procedural efficiency. While the study was promising, the lack of long-term outcomes highlights the need for further evaluation. The session underscored the ongoing evolution in electrophysiology, encouraging future innovation and rigorous safety standards.

Keywords

VOLT-AF-IDE trial

catheter technology

atrial fibrillation

pulse field ablation

electrophysiology